Reports
Reports
Sale
The telmisartan market size was valued at USD 3.57 billion in 2023, driven by the rising prevalence of cardiovascular diseases across the major markets. The market is expected to grow at a CAGR of 5.6% during the forecast period of 2024-2032, with the values likely to rise from USD 3.77 billion in 2024 to USD 5.83 billion by 2032.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
Telmisartan is an angiostatin II receptor blocker used to treat hypertension (high blood pressure). It works by relaxing the blood vessels to facilitate better blood flow and is commonly used to prevent strokes, kidney issues, and heart attacks. It is available in tablet form and is ingested through the mouth. Common dosage sizes include 20 mg, 40 mg, and 80 mg, which may be prescribed based on the patient’s condition.
The growth of the market is being driven by the prevalence and rise in diseases like hypertension and other cardiovascular diseases like strokes and cardiac arrests. The robust growth of the pharmaceutical sector is supplementing the growth of telmisartan to treat chronic diseases like those related to the cardiovascular system. Telmisartan works against high blood pressure by being effective in gene modification for insulin sensitization and regulating glucose and lipid metabolism. Significant contributions towards research and development (R&D) projects to explore the various benefits of telmisartan in the treatment of diabetic nephropathy and other kidney disorders are generating growth opportunities for industry growth. In addition, pharmaceutical manufacturers are working towards the development of generic versions of telmisartan medications to provide cost-effective treatment to patients suffering from hypertension and other cardiovascular diseases, consequently augmenting the telmisartan market growth.
With a deeper understanding of technology, rising advancements and growing demand for telmisartan, novel synthesizing methods have emerged in the market. Researchers have been using a high-yielding Suzuki reaction, which has increased the yield production up to 83%.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
Market Breakup by Strength
Market Breakup by Indication
Market Breakup by Distribution Channel
Market Breakup by Region
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
With a high prevalence of cardiovascular diseases, North America has dominated the telmisartan market share in the historical period. The presence of key healthcare players and well-developed research infrastructure has majorly contributed to the market share. In addition, mergers and acquisitions amongst impactful companies to increase their product portfolio and offer better treatment solutions to patients have also impacted the market positively.
In Europe, the increasing integration of novel technologies into the medical ecosystem has contributed to substantial market growth. The presence of research and academic institutions also aids in the development of innovative solutions for the patients. The government of major countries like the United Kingdom, Spain, and France provide relevant awareness about cardiovascular diseases allowing them to opt for correct medications for their condition.
The key features of the market report include patent analysis, grants analysis, clinical trials analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players. The major companies in the market are as follows:
Kindly note that this only represents a partial list of companies, and the complete list has been provided in the report.
REPORT FEATURES | DETAILS |
Base Year | 2023 |
Historical Period | 2017-2023 |
Forecast Period | 2024-2032 |
Scope of the Report |
Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:
|
Breakup by Strength |
|
Breakup by Indication |
|
Breakup by Distribution Channel |
|
Breakup by Region |
|
Market Dynamics |
|
Competitive Landscape |
|
Companies Covered |
|
*At Expert Market Research, we strive to always give you current and accurate information. The numbers depicted in the description are indicative and may differ from the actual numbers in the final EMR report.
1 Preface
1.1 Objectives of the Study
1.2 Key Assumptions
1.3 Report Coverage – Key Segmentation and Scope
1.4 Research Methodology
2 Executive Summary
3 Hypertension Overview
3.1 Guidelines and Stages
3.2 Pathophysiology
3.3 Screening and Diagnosis
3.4 Treatment Pathway
4 Patient Profile
4.1 Patient Profile Overview
4.2 Patient Psychology and Emotional Impact Factors
4.3 Risk Assessment and Treatment Success Rate
5 Hypertension Epidemiology Analysis – 7MM
5.1 7MM Epidemiology Scenario Overview (2017-2032)
5.2 United States Hypertension Epidemiology Forecast (2017-2032)
5.3 EU-4 and United Kingdom Hypertension Epidemiology (2017-2032)
5.3.1 Germany Hypertension Epidemiology Forecast (2017-2032)
5.3.2 France Hypertension Epidemiology Forecast (2017-2032)
5.3.3 Italy Hypertension Epidemiology Forecast (2017-2032)
5.3.4 Spain Hypertension Epidemiology Forecast (2017-2032)
5.3.5 United Kingdom Hypertension Epidemiology Forecast (2017-2032)
5.4 Japan Hypertension Epidemiology (2017-2032)
6 Telmisartan Market Overview – 7MM
6.1 Telmisartan Market Historical Value (2017-2023)
6.2 Telmisartan Market Forecast Value (2024-2032)
7 Telmisartan Market Landscape – 7MM
7.1 Telmisartan Developers Landscape
7.1.1 Analysis by Year of Establishment
7.1.2 Analysis by Company Size
7.1.3 Analysis by Region
7.2 Telmisartan Product Landscape
7.2.1 Analysis by Strength
7.2.2 Analysis by Indication
7.2.3 Analysis by Distribution Channel
8 Telmisartan Market Dynamics
8.1 Market Drivers and Constraints
8.2 SWOT Analysis
8.3 Porter’s Five Forces Model
8.4 Key Demand Indicators
8.5 Key Price Indicators
8.6 Industry Events, Initiatives, and Trends
8.7 Value Chain Analysis
9 Telmisartan Market Segmentation – 7MM
9.1 Telmisartan Market by Strength
9.1.1 Market Overview
9.1.2 20 mg
9.1.3 40 mg
9.1.4 80 mg
9.2 Telmisartan Market by Indication
9.2.1 Market Overview
9.2.2 Hypertension
9.2.3 Stroke
9.2.4 Cardiac Arrest
9.2.5 Others
9.3 Telmisartan Market by Distribution Channel
9.3.1 Market Overview
9.3.2 Hospital Pharmacies
9.3.3 Retail Pharmacies
9.3.4 Online Pharmacies
9.4 Telmisartan Market by Region
9.4.1 Market Overview
9.4.2 United States
9.4.3 EU-4 and the United Kingdom
9.4.3.1 Germany
9.4.3.2 France
9.4.3.3 Italy
9.4.3.4 Spain
9.4.3.5 United Kingdom
9.4.4 Japan
10 United States Telmisartan Market
10.1 Telmisartan Market Historical Value (2017-2023)
10.2 Telmisartan Market Forecast Value (2024-2032)
10.3 Telmisartan Market by Indication
11 EU-4 and United Kingdom Telmisartan Market
11.1 Telmisartan Market Historical Value (2017-2023)
11.2 Telmisartan Market Forecast Value (2024-2032)
11.3 Germany Telmisartan Market Overview
11.3.1 Telmisartan Market by Indication
11.4 France Telmisartan Market Overview
11.4.1 Telmisartan Market by Indication
11.5 Italy Telmisartan Market Overview
11.5.1 Telmisartan Market by Indication
11.6 Spain Telmisartan Market Overview
11.6.1 Telmisartan Market by Indication
11.7 United Kingdom Telmisartan Market Overview
11.7.1 Telmisartan Market by Indication
12 Japan Telmisartan Market
12.1 Telmisartan Market Historical Value (2017-2023)
12.2 Telmisartan Market Forecast Value (2024-2032)
12.3 Telmisartan Market by Indication
13 Regulatory Framework
14 Patent Analysis
14.1 Analysis by Type of Patent
14.2 Analysis by Publication year
14.3 Analysis by Issuing Authority
14.4 Analysis by Patent Age
14.5 Analysis by CPC Analysis
14.6 Analysis by Patent Valuation
14.7 Analysis by Key Players
15 Clinical Trials Analysis
15.1 Analysis by Trial Registration Year
15.2 Analysis by Trial Status
15.3 Analysis by Trial Phase
15.4 Analysis by Therapeutic Area
15.5 Analysis by Geography
16 Funding and Investment Analysis
16.1 Analysis by Funding Instances
16.2 Analysis by Type of Funding
16.3 Analysis by Funding Amount
16.4 Analysis by Leading Players
16.5 Analysis by Leading Investors
16.6 Analysis by Geography
17 Partnership and Collaborations Analysis
17.1 Analysis by Partnership Instances
17.2 Analysis by Type of Partnership
17.3 Analysis by Leading Players
17.4 Analysis by Geography
18 Supplier Landscape
18.1 Novartis AG
18.1.1 Financial Analysis
18.1.2 Product Portfolio
18.1.3 Demographic Reach and Achievements
18.1.4 Mergers and Acquisitions
18.1.5 Certifications
18.2 Astellas Pharma Inc.
18.2.1 Financial Analysis
18.2.2 Product Portfolio
18.2.3 Demographic Reach and Achievements
18.2.4 Mergers and Acquisitions
18.2.5 Certifications
18.3 Nippon Boehringer Ingelheim
18.3.1 Financial Analysis
18.3.2 Product Portfolio
18.3.3 Demographic Reach and Achievements
18.3.4 Mergers and Acquisitions
18.3.5 Certifications
18.4 Abbott
18.4.1 Financial Analysis
18.4.2 Product Portfolio
18.4.3 Demographic Reach and Achievements
18.4.4 Mergers and Acquisitions
18.4.5 Certifications
18.5 Hema Pharmaceuticals Pvt. Ltd.
18.5.1 Financial Analysis
18.5.2 Product Portfolio
18.5.3 Demographic Reach and Achievements
18.5.4 Mergers and Acquisitions
18.5.5 Certifications
18.6 Pfizer Inc.
18.6.1 Financial Analysis
18.6.2 Product Portfolio
18.6.3 Demographic Reach and Achievements
18.6.4 Mergers and Acquisitions
18.6.5 Certifications
18.7 Aurobindo Pharma
18.7.1 Financial Analysis
18.7.2 Product Portfolio
18.7.3 Demographic Reach and Achievements
18.7.4 Mergers and Acquisitions
18.7.5 Certifications
18.8 Sun Pharmaceutical Industries Limited
18.8.1 Financial Analysis
18.8.2 Product Portfolio
18.8.3 Demographic Reach and Achievements
18.8.4 Mergers and Acquisitions
18.8.5 Certifications
18.9 Glaxosmithkline (GSK)
18.9.1 Financial Analysis
18.9.2 Product Portfolio
18.9.3 Demographic Reach and Achievements
18.9.4 Mergers and Acquisitions
18.9.5 Certifications
18.10 Zydus Cadila
18.10.1 Financial Analysis
18.10.2 Product Portfolio
18.10.3 Demographic Reach and Achievements
18.10.4 Mergers and Acquisitions
18.10.5 Certifications
18.11 Teva Pharmaceutical Industries Ltd. (Actavis Generics)
18.11.1 Financial Analysis
18.11.2 Product Portfolio
18.11.3 Demographic Reach and Achievements
18.11.4 Mergers and Acquisitions
18.11.5 Certifications
18.12 Sanofi SA
18.12.1 Financial Analysis
18.12.2 Product Portfolio
18.12.3 Demographic Reach and Achievements
18.12.4 Mergers and Acquisitions
18.12.5 Certifications
18.13 Mylan N.V.
18.13.1 Financial Analysis
18.13.2 Product Portfolio
18.13.3 Demographic Reach and Achievements
18.13.4 Mergers and Acquisitions
18.13.5 Certifications
18.14 Cipla Inc.
18.14.1 Financial Analysis
18.14.2 Product Portfolio
18.14.3 Demographic Reach and Achievements
18.14.4 Mergers and Acquisitions
18.14.5 Certifications
19 Telmisartan Market - Distribution Model (Additional Insight)
19.1 Overview
19.2 Potential Distributors
19.3 Key Parameters for Distribution Partner Assessment
20 Key Opinion Leaders (KOL) Insights (Additional Insight)
21 Company Competitiveness Analysis (Additional Insight)
21.1 Very Small Companies
21.2 Small Companies
21.3 Mid-Sized Companies
21.4 Large Companies
21.5 Very Large Companies
22 Payment Methods (Additional Insight)
22.1 Government Funded
22.2 Private Insurance
22.3 Out-of-Pocket
*Additional insights provided are customisable as per client requirements.
The market attained a value of about USD 3.57 billion in 2023, driven by the rising incidence of cardiovascular diseases across major markets.
The market is anticipated to grow at a CAGR of 5.6% during the forecast period of 2024-2032, likely to reach a market value of USD 5.83 billion by 2032.
The high market demand is driven growing investments in the research and development (R&D) projects to explore the development of telmisartan in the treatment of diabetes and other chronic diseases as well.
Major market trends involve the application of synthetic methods to synthesize the medication.
Based on strength, the market is divided into 20 mg, 40 mg, and 80 mg.
Hypertension, stroke, and cardiac arrest, among others are some of the common indication types.
Major distribution channels include hospital pharmacies, retail pharmacies, and online pharmacies.
The major regions of the market include the United States, Japan, the United Kingdom, and EU-4. EU-4 is further segmented into Germany, France, Italy, Spain, and the United Kingdom.
Key players involved in the market are Novartis AG, Astellas Pharma Inc., Nippon Boehringer Ingelheim, Abbott, Hema Pharmaceuticals Pvt. Ltd., Pfizer Inc., Aurobindo Pharma, Sun Pharmaceutical Industries Limited, Glaxosmithkline (GSK), Zydus Cadila, Teva Pharmaceutical Industries Ltd. (Actavis Generics), Sanofi SA, Mylan N.V. and Cipla Inc.
Mini Report
Single User License
Five User License
Corporate License
Any Question? Speak With An Analyst
View A Sample
Did You Miss Anything, Ask Now
Right People
We are technically excellent, strategic, practical, experienced and efficient; our analysts are hand-picked based on having the right attributes to work successfully and execute projects based on your expectations.
Right Methodology
We leverage our cutting-edge technology, our access to trusted databases, and our knowledge of the current models used in the market to deliver you research solutions that are tailored to your needs and put you ahead of the curve.
Right Price
We deliver in-depth and superior quality research in prices that are reasonable, unmatchable, and shows our understanding of your resource structure. We, additionally, offer attractive discounts on our upcoming reports.
Right Support
Our team of expert analysts are at your beck and call to deliver you optimum results that are customised to meet your precise needs within the specified timeframe and help you form a better understanding of the industry.